Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
192 participants
OBSERVATIONAL
2019-10-30
2020-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This disease is rare and its clinical, EEG and radiological characterisation is not sufficiently established. The investigators will evaluate these three aspects for the anti-LGI1 cohort of patients of the National Reference Center of autoimmune encephalitis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Core Cerebrospinal Fluid Biomarker Profile in Anti-Leucine Rich Glioma Inactivated 1 (Anti-LGI1) Encephalitis
NCT04001270
BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
NCT05825690
HLA Analysis in Autoimmune Encephalitis and Related Disorders
NCT04106596
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
NCT06173076
Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease
NCT06515106
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
: epileptic LGI1-antibody patients
Patients affected by LGI1 antibody encephalitis presenting epileptic seizures as a first symptom
Evaluated items:
* Number of seizures
* Type of seizures
* Presence of EEG abnormalities
* Presence of IRM abnormalities
* Time before cognitive disorders
No interventions assigned to this group
cognitive LGI1-antibody patients
Patients affected by LGI1 antibody encephalitis presenting cognitive disorders as a first symptom
Evaluated items:
* Presence of EEG abnormalities
* Presence of IRM abnormalities
* Time before epileptic seizures
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of anti-LGI1 encephalitis based on sera or CSF samples in the National Reference Center of autoimmune encephalitis from 2011/06 to 2019 july 1st.
* Clinical follow-up in France
Exclusion Criteria
* Foreign follow-up
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerome HONNORAT, pHd
Role: PRINCIPAL_INVESTIGATOR
National Reference Center of autoimmune encephalitis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
evoLGI1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.